Headwinds in remission; revenues of ICRA’s sample set of Indian API companies to grow by 7-8% and operating profit margin to improve to 12-14% in FY2025: ICRA Read more
Credit profile of Indian pharma cos to remain healthy in FY2025 despite moderation in revenue growth: ICRA Read more
Stability of input costs, specialty product launches to support performance of Indian pharma companies in FY2024: ICRA Read more
Pricing pressures and regulatory overhang affect margins of Indian pharma companies in FY2023: ICRA Read more